about
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinasesSuppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancerDo mountain bikers have a higher risk of scrotal disorders than on-road cyclists?A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases.PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cellsAkacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivoPIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.RNA expression signatures and posttranscriptional regulation in diabetic nephropathy.Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture.Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.Multi-chamber electroosmosis using textile reinforced agar membranes--A promising concept for the future of hemodialysis.Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling.Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion.Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.Dabigatran pharmacokinetics--implications for treatment.The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells.[Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion].Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells.Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.A rare case of Epstein-Barr virus-associated hepatosplenic smooth muscle tumors after kidney transplantation.Extending the spectrum of a chameleon: IgG4-related disease appearing as interstitial nephritis and mimicking anti-neutrophil cytoplasmic antibody-associated vasculitis.Good Results with Individually Adapted Long-Term Immunosuppression Following Alemtuzumab Versus ATG Induction Therapy in Combined Kidney-Pancreas Transplantation: A Single-Center ReportA rare case of milky urineThree-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuriaThe antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1Value of 3-dimensional transrectal/transvaginal sonography in diagnosis of distal ureteral calculiPersistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladderFetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate developmentSuccinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer CellsIs There Decreasing Public Interest in Renal Transplantation? A Google TrendsTM AnalysisEfficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk-A Single Center ExperienceArterial Hypertension as a Risk Factor for Reduced Glomerular Filtration Rate after Living Kidney Donation
P50
Q24656365-BF945E21-F535-4A8C-9DDB-0323302192E6Q24677026-0563AB12-0CF2-4BA6-8B20-3A2C7FDD3FD4Q34734449-0BC5531B-14E6-4A97-9023-45DF829544AAQ34995501-22A68F9B-4609-42CC-9F63-F51650F59C8CQ35068026-03B27BA9-CE2D-400C-BA37-D0F3E6EDE20DQ35101648-26B9704B-A514-4A04-AA51-65127DAE66FFQ36896806-F45FE0C7-92BC-4A62-B43A-BC8B8AF0B88AQ38553920-C8D9246E-B7D5-4557-B22C-0FCA7442EFF7Q38748082-D978E462-B4D1-47E3-9049-376C899FCAC1Q38829200-CEA22225-0627-4EF5-8121-750A9E495361Q38942430-0C93E9B9-B022-4FD6-B93C-21ECA5F33100Q39265081-A4C97FF8-3933-4C3E-A827-FE743F083E04Q39723360-BA486461-DDED-4848-A06F-D768D005D49DQ39801989-E7668B0A-3752-47F4-8ABA-2E0355D2528BQ39916314-B9276AB7-0A60-4629-8BB0-71A15133B423Q40043223-0C30D86B-FBD2-4B52-90F6-C066A25F231FQ40129061-B3DB166D-C8CB-4D44-8C54-8ED24F639CA4Q44771352-195E9843-D065-448D-AAF4-9C52276E6735Q45229482-A65919FE-C81F-4CA2-BEF9-ABB840F497D6Q45919182-89000E54-84C6-448E-ACC3-5B79D471908CQ47588581-59A371EF-924A-4042-BE96-716FCF3E56DAQ50054682-3EF782D8-0AEE-456F-8EC4-30F535639002Q50088485-2EC70CBA-B9BD-4C82-8810-9646260F51EFQ53431879-02E7E59D-BB76-41CC-AF36-FAF005F2A2EFQ61808801-7A4A8699-35D3-438F-86F3-B9CE4601CA02Q64042302-D6D60DA6-3712-4EA1-BA20-FCD603884AB0Q79223944-D5897FEF-4D8F-42D3-90F0-85A7D351BC74Q79314186-2962CE48-D5CB-4EEC-8AE0-EF97068F3093Q79445269-591F706D-A7BF-4C86-8DAD-D39D32D04D48Q79629709-40A79097-9E69-4E11-B0BB-1A7447792369Q80490419-C5364E5D-BC9A-4345-8C01-60F457CB94F2Q90420498-B0B8AAF2-D57B-47E5-AF61-F7ED34096477Q91781143-C89E1CA2-CBA6-44C0-BE01-0918A63680A5Q92422476-EB441AF6-1771-496C-B326-D7FA5CB07B2FQ93006220-15DC5A83-525B-4FC4-A79A-4268CF54619C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hannes Neuwirt
@ast
Hannes Neuwirt
@en
Hannes Neuwirt
@es
Hannes Neuwirt
@nl
type
label
Hannes Neuwirt
@ast
Hannes Neuwirt
@en
Hannes Neuwirt
@es
Hannes Neuwirt
@nl
prefLabel
Hannes Neuwirt
@ast
Hannes Neuwirt
@en
Hannes Neuwirt
@es
Hannes Neuwirt
@nl
P106
P31
P496
0000-0003-1064-0098